Key Points – Dr.
Martens posted a 59% rise in adjusted profit before tax to £54.2 million even as revenue slipped 1.4% on a constant-currency basis, helped by lower markdowns, higher gross margin and tighter cost control. – The company said its consumer-first strategy is improving sales quality in the Americas and APAC, where full-price sales and average selling prices rose, while EMEA remained under pressure due to a weak and promotional market, especially in the U.K. and Germany. – Dr
Martens continued to strengthen its balance sheet, with net debt falling and leverage ending at 1.4x EBITDA, while management outlined FY 2027 priorities including better full-price mix in Europe, new sandals, store-format changes and further brand investment. Dr. Martens (LON:DOCS) reported higher full-year profit despite slightly lower revenue, as management said the footwear brand prioritized full-price sales, reduced markdown activity and continued to reshape the business around a consumer-led strategy.
Speaking at the company’s FY 2026 results presentation, Chief Executive Officer Ije Nwokorie said the strategy introduced last year was intended to move Dr. Martens “from a channel-first mindset to a consumer-first mindset” and build greater brand desire globally. Chief Financial Officer Giles Wilson said the year involved “significant change, some really tough calls, and a lot of hard work” as the company sought to improve revenue quality while maintaining cost discipline.